NovoCure Limited Ordinary Shares
Here’s whether NovoCure Limited Ordinary Shares (NVCR) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+3.85% over 10 days); 3-month momentum positive (+36.3%); rising volume confirms the move (1.34x 30d avg). Concerns: RSI 82 — overbought, elevated pullback risk. Currently 17.1% off its 52-week high. Score: +5/7.
NVCR is in a confirmed uptrend, trading above both its 50-day ($12.23) and 200-day ($12.56) moving averages. With an RSI of 81.7, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of -7.4% compares to +27.9% for SPY (trailed the market by 35.3%).